| Jan 26, 2026 | Jixing Pharmaceuticals | $287.0M Series D | — | Adage Capital Management, HBM Healthcare Investments, Hengdian Group Capital, RA Capital Management, Roderick Wong, Silver Arc Private Capital, SR One, SymBiosis, TCGX |
| Jan 12, 2026 | Mirador Therapeutics | $250.0M Series B | — | Adage Capital Management, ARCH Venture Partners, Boxer Capital, Fairmount, Farallon Capital Management, Fidelity Management & Research Company, Logos Capital, OrbiMed, Point72, TCGX, T. Rowe Price Associates, Venrock, Woodline Partners |
| Jan 8, 2026 | Parabilis Medicines | $305.0M Series F | Jake Simson | Catalio Capital Management, Foresite Capital, ARCH Venture Partners, Cormorant Asset Management, Farallon Capital Management, Frazier Life Sciences, Freepoint Capital Group, General Catalyst, HBM Healthcare Investments, Marshall Wace, Milky Way Investments, Nextech Invest, Rock Springs Capital, Sixty Degree Capital, Soleus Capital, T. Rowe Price Associates |
| Dec 9, 2025 | Sanegene Bio | $110.0M Series B | — | Eli Lilly and Company, K2 Venture Partners, Lake Bleu Capital, Legend Capital, Northern Light Venture Capital, Oriza Holdings, Qiming Venture Partners, Sino Biopharmaceutical, SymBiosis, Tencent, TF Capital, TruMed, Vivo Capital |
| Dec 3, 2025 | Triana Biomedicines | $120.0M Series B | Lorence Kim, Andrew Hedin | Atlas Venture, Finchley Healthcare Ventures, Lightspeed Venture Partners, RA Capital Management, Regeneron Ventures, Surveyor Capital, YK Bioventures |
| Nov 1, 2025 | Artios Pharma | $120.0M Series D | Jake Simson, Nikola Trbovic | Andera Partners, EQT Life Sciences, Hakan Goker, M Ventures (Merck), Novartis Venture Fund, Pfizer Venture Investments, Avidity Partners, Janus Henderson Investors, LSP, Novartis, Omega Funds, Piper Heartland Healthcare Capital, Schroders Capital, Sofinnova Partners |
| Oct 16, 2025 | Veradermics | $150.0M Series C | Katarina Pance | abrdn, Infinitium, LifeSci Venture Partners, Longitude Capital, Marshall Wace, Surveyor Capital, Suvretta Capital Management, Viking Global Investors |
| Oct 1, 2025 | Kailera Therapeutics | $600.0M Series B | Andrew Kaplan | Bain Capital, Gotham Makker, Michael Gladstone, Adage Capital Management, Atlas Venture, Bain Capital Life Sciences, Janus Henderson Investors, Perseverance Capital Management, Qatar Investment Authority, Royalty Pharma, Roderick Wong, Sirona Capital, Surveyor Capital, T. Rowe Price Associates |
| Oct 1, 2025 | Hemab | $160.0M Series C | Soffinova Partners | Access Biotechnology, Amzak Health Investors, HealthCap, Avoro Capital Advisors, Deep Track Capital, Maj Invest, Novo Holdings, RA Capital Management, Rock Springs Capital |
| Jul 17, 2025 | One Biosciences | $17.4M Series A | Blast.Club, Redmile Group | Adamed Technology, Galion.exe, Kima Ventures, Polytechnique Ventures, Sofinnova Partners |
| Jun 5, 2025 | Aive | $14.1M Series A | Benedetto Staccia | — |
| May 1, 2025 | Antares Therapeutics | $180.0M Series A | Atlas Venture, Shelley Chu, Otello Stampacchia, BVF Partners, Cormorant Asset Management | Frazier Healthcare Partners, Polaris Partners, Vida Ventures, Tenmile, Vinyanshu Ventures, Willett Advisors, Abingworth |
| Oct 1, 2024 | Seaport Therapeutics | $230.0M Series B | General Atlantic | venBio, ARCH Venture Partners, Foresite Capital, Goldman Sachs, Bharatt Chowrira, Sofinnova Ventures, Third Rock Ventures, T. Rowe Price Associates |
| May 13, 2024 | Lycia Therapeutics | $106.6M Series C | Andrew Gottesdiener | Eli Lilly and Company, Franklin Templeton, Janus Henderson Investors, Marshall Wace, Redmile Group, RTW Investments |
| Apr 1, 2024 | Endeavor BioMedicines | $130.0M Series C | AyurMaya, Karan Takhar | Atlas Venture, Hatteras Venture Partners, Omega Funds, RA Capital, Roche Venture Fund, abrdn, Ally Bridge Group, Avidity Partners, Eckuity Capital, Fidelity Management & Research Company, Longitude Capital, Perceptive Advisors, Piper Heartland Healthcare Capital, Silver Arch Bio, SymBiosis, T. Rowe Price Associates, Velosity Capital, Woodline Partners |
| Apr 1, 2024 | Alterome Therapeutics | $130.0M Series B | Josh Richardson | Andera Partners, Nextech Invest, OrbiMed, venBio, Vida Ventures, Boxer Capital, Uwe Schoenbeck, Colt Ventures, Digitalis Ventures, Driehaus Capital Management, Nextech Invest |
| Mar 1, 2024 | Mirador Therapeutics | $400.0M Series A | ARCH Venture Partners | Cambridge Innovation Capital, HealthCap, Mubadala, Alexandria Venture Investments, Boxer Capital, Fairmount, Farallon Capital Management, Fidelity Management & Research Company, Logos Capital, OrbiMed, Point72, RTW Investments, Sanofi Ventures, TCGX, Venrock, Woodline Partners |
| Mar 1, 2024 | Pi Health | $31.0M Series A | AlleyCorp, Obvious Ventures | Alumni Ventures, Fika Ventures, FPV Fund, General Catalyst, Greycroft, Homebrew, Jazz Venture Partners, Kavita Patel, Northzone, Cherian Mathew, Gokul Rajaram |
| Feb 1, 2024 | FogPharma | $150.0M Series E | Thilo Schroeder | Lux Capital, Nextech Invest, The Column Group, venBio, Alex Gorsky, ARCH Venture Partners, Catalio Capital Management, Cormorant Asset Management, Farallon Capital Management, Fidelity Management & Research Company, Foresite Capital, General Catalyst, Google Ventures, Marshall Wace, Milky Way Investments, RA Capital Management, Rock Springs Capital, Samsara BioCapital, Sixty Degree Capital, SymBiosis, T. Rowe Price Associates |
| Feb 1, 2024 | NextPoint Therapeutics | $43.0M Series B | Jacob Vogelstein | ARCH Venture Partners, Atlas Venture, Catalio Capital, MPM Capital, Polaris Partners, Gordon Freeman, Arkin Bio Ventures, Binney Street Capital, Leaps by Bayer, Sanofi Ventures, Sixty Degree Capital, WTT Investment |
| Oct 1, 2023 | Engine Biosciences | $27.0M Series A | Amy Schulman | HealthQuest Capital, Koch Fund, Lightspeed Venture Partners, Polaris Partners, Ali Farahanchi, Wen Qi Ho, EDBI, SEEDS Capital |
| Sep 6, 2023 | PayJoy | $360.0M Debt / Series C | Citi, Warburg Pincus | Citi Ventures, Greylock Partners, Union Square Ventures |
| Aug 1, 2023 | ADARx Pharmaceuticals | $200.0M Series C | Ricky Sun, Chen Yu | Andreessen Horowitz, Frazier Healthcare Partners, Ed Mathers, OrbiMed, SR One, Third Rock Ventures, Ascenta Capital, BlackRock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Lilly Asia Ventures, Redmile Group, T. Rowe Price Associates, Venrock, Vivo Capital |
| Aug 1, 2023 | Tisento Therapeutics | $81.0M Series A | — | Peter M. Hecht, J. Wood Capital, Polaris, Sanofi Ventures, Venrock |
| Jul 31, 2023 | tisento | $81.0M Series A | — | Peter M. Hecht, J. Wood Capital, Polaris, Sanofi Ventures, Bryan Roberts |
